Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 54

1.

Mammalian target of rapamycin: discovery of rapamycin reveals a signaling pathway important for normal and cancer cell growth.

Gibbons JJ, Abraham RT, Yu K.

Semin Oncol. 2009 Dec;36 Suppl 3:S3-S17. doi: 10.1053/j.seminoncol.2009.10.011. Review.

PMID:
19963098
2.

Differential regulation of NHE1 phosphorylation and glucose uptake by inhibitors of the ERK pathway and p90RSK in 3T3-L1 adipocytes.

Chen S, Mackintosh C.

Cell Signal. 2009 Dec;21(12):1984-93. doi: 10.1016/j.cellsig.2009.09.009. Epub 2009 Sep 15.

3.

Response and resistance to MEK inhibition in leukaemias initiated by hyperactive Ras.

Lauchle JO, Kim D, Le DT, Akagi K, Crone M, Krisman K, Warner K, Bonifas JM, Li Q, Coakley KM, Diaz-Flores E, Gorman M, Przybranowski S, Tran M, Kogan SC, Roose JP, Copeland NG, Jenkins NA, Parada L, Wolff L, Sebolt-Leopold J, Shannon K.

Nature. 2009 Sep 17;461(7262):411-4. doi: 10.1038/nature08279. Epub 2009 Sep 2.

4.

NF2/merlin is a novel negative regulator of mTOR complex 1, and activation of mTORC1 is associated with meningioma and schwannoma growth.

James MF, Han S, Polizzano C, Plotkin SR, Manning BD, Stemmer-Rachamimov AO, Gusella JF, Ramesh V.

Mol Cell Biol. 2009 Aug;29(15):4250-61. doi: 10.1128/MCB.01581-08. Epub 2009 May 18.

5.

The pharmacology of mTOR inhibition.

Guertin DA, Sabatini DM.

Sci Signal. 2009 Apr 21;2(67):pe24. doi: 10.1126/scisignal.267pe24.

PMID:
19383975
6.

EGFR signals to mTOR through PKC and independently of Akt in glioma.

Fan QW, Cheng C, Knight ZA, Haas-Kogan D, Stokoe D, James CD, McCormick F, Shokat KM, Weiss WA.

Sci Signal. 2009 Jan 27;2(55):ra4. doi: 10.1126/scisignal.2000014. Erratum in: Sci Signal. 2009;2(60):er4.

7.

Oncogenic MAPK signaling stimulates mTORC1 activity by promoting RSK-mediated raptor phosphorylation.

Carrière A, Cargnello M, Julien LA, Gao H, Bonneil E, Thibault P, Roux PP.

Curr Biol. 2008 Sep 9;18(17):1269-77. doi: 10.1016/j.cub.2008.07.078. Epub 2008 Aug 21.

8.

Regulation of TORC1 by Rag GTPases in nutrient response.

Kim E, Goraksha-Hicks P, Li L, Neufeld TP, Guan KL.

Nat Cell Biol. 2008 Aug;10(8):935-45. doi: 10.1038/ncb1753. Epub 2008 Jul 6.

9.

The Rag GTPases bind raptor and mediate amino acid signaling to mTORC1.

Sancak Y, Peterson TR, Shaul YD, Lindquist RA, Thoreen CC, Bar-Peled L, Sabatini DM.

Science. 2008 Jun 13;320(5882):1496-501. doi: 10.1126/science.1157535. Epub 2008 May 22.

10.

The TSC1-TSC2 complex: a molecular switchboard controlling cell growth.

Huang J, Manning BD.

Biochem J. 2008 Jun 1;412(2):179-90. doi: 10.1042/BJ20080281. Review.

11.

The binding of PRAS40 to 14-3-3 proteins is not required for activation of mTORC1 signalling by phorbol esters/ERK.

Fonseca BD, Lee VH, Proud CG.

Biochem J. 2008 Apr 1;411(1):141-9. doi: 10.1042/BJ20071001.

PMID:
18215133
12.

The selectivity of protein kinase inhibitors: a further update.

Bain J, Plater L, Elliott M, Shpiro N, Hastie CJ, McLauchlan H, Klevernic I, Arthur JS, Alessi DR, Cohen P.

Biochem J. 2007 Dec 15;408(3):297-315.

13.

PRAS40 is a target for mammalian target of rapamycin complex 1 and is required for signaling downstream of this complex.

Fonseca BD, Smith EM, Lee VH, MacKintosh C, Proud CG.

J Biol Chem. 2007 Aug 24;282(34):24514-24. Epub 2007 Jun 29.

14.

mTOR and cancer therapy.

Easton JB, Houghton PJ.

Oncogene. 2006 Oct 16;25(48):6436-46. Review.

PMID:
17041628
15.

Upstream of the mammalian target of rapamycin: do all roads pass through mTOR?

Corradetti MN, Guan KL.

Oncogene. 2006 Oct 16;25(48):6347-60. Review.

PMID:
17041621
16.

BI-D1870 is a specific inhibitor of the p90 RSK (ribosomal S6 kinase) isoforms in vitro and in vivo.

Sapkota GP, Cummings L, Newell FS, Armstrong C, Bain J, Frodin M, Grauert M, Hoffmann M, Schnapp G, Steegmaier M, Cohen P, Alessi DR.

Biochem J. 2007 Jan 1;401(1):29-38.

17.

Current development of mTOR inhibitors as anticancer agents.

Faivre S, Kroemer G, Raymond E.

Nat Rev Drug Discov. 2006 Aug;5(8):671-88.

PMID:
16883305
18.

Activity of TSC2 is inhibited by AKT-mediated phosphorylation and membrane partitioning.

Cai SL, Tee AR, Short JD, Bergeron JM, Kim J, Shen J, Guo R, Johnson CL, Kiguchi K, Walker CL.

J Cell Biol. 2006 Apr 24;173(2):279-89.

19.

BRAF mutation predicts sensitivity to MEK inhibition.

Solit DB, Garraway LA, Pratilas CA, Sawai A, Getz G, Basso A, Ye Q, Lobo JM, She Y, Osman I, Golub TR, Sebolt-Leopold J, Sellers WR, Rosen N.

Nature. 2006 Jan 19;439(7074):358-62. Epub 2005 Nov 6.

20.

The NF1 tumor suppressor critically regulates TSC2 and mTOR.

Johannessen CM, Reczek EE, James MF, Brems H, Legius E, Cichowski K.

Proc Natl Acad Sci U S A. 2005 Jun 14;102(24):8573-8. Epub 2005 Jun 3. Erratum in: Proc Natl Acad Sci U S A. 2005 Nov 1;102(44):16119.

Items per page

Supplemental Content

Write to the Help Desk